Unmet Needs in Japanese Patients Who Report Insufficient Efficacy with Triptans for Acute Treatment of Migraine: Retrosp
- PDF / 665,044 Bytes
- 18 Pages / 595.276 x 790.866 pts Page_size
- 65 Downloads / 136 Views
ORIGINAL RESEARCH
Unmet Needs in Japanese Patients Who Report Insufficient Efficacy with Triptans for Acute Treatment of Migraine: Retrospective Analysis of RealWorld Data Koichi Hirata . Kaname Ueda
. Mika Komori . Wenyu Ye .
Yongin Kim . Sarah Cotton . James Jackson . Tamas Treuer
Received: September 28, 2020 / Accepted: November 19, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: Migraine attacks notably impact people’s daily lives, health-related quality of life (HRQoL), and ability to work. Triptans are widely used as acute medication for a migraine attack but are ineffective, poorly tolerated, or contraindicated in some patients. HRQoL and work productivity are therefore likely to pose particular problems for patients whose migraine attacks do not respond sufficiently to triptan acute treatment. This real-world study aimed to determine whether migraine-related HRQoL, disability, and work productivity differed between triptan insufficient responders (TIRs) Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40122020-00223-y) contains supplementary material, which is available to authorized users. K. Hirata Department of Neurology, Dokkyo Medical University, Tochigi, Japan K. Ueda (&) M. Komori Eli Lilly Japan K.K, Kobe, Japan e-mail: [email protected] W. Ye Y. Kim Eli Lilly and Company, Indianapolis, IN, USA S. Cotton J. Jackson Adelphi Real World, Bollington, UK T. Treuer Lilly Hunga´ria Kft, Budapest, Hungary
and sufficient responders (TSRs) receiving this acute treatment for migraine in Japan. Methods: This was a retrospective analysis of 2017 Adelphi Migraine Disease Specific Programme cross-sectional survey data collected from physicians and their consulting patients with migraine in Japan. Patients had to be receiving a triptan as their sole acute prescribed medication for migraine. TIRs were defined as patients who achieved headache pain freedom within 2 h of taking triptan acute treatment in no more than three of five migraine attacks. Differences in outcomes between TIRs and TSRs were examined in adjusted analyses using a multivariable general linear model. Results: Of 200 patients receiving a triptan as their sole prescribed acute treatment for migraine, 88 (44.0%) were classed as TIRs. Migraine-Specific Quality of Life Questionnaire scores were significantly lower—indicating poorer HRQoL—among TIRs than TSRs, as were mean EuroQol 5-dimension utility and visual analog scale scores (p \ 0.05 for comparisons). TIRs also reported significantly (p B 0.003) greater impairment than TSRs across all Work Productivity and Activity Impairment domains, with the exception of work time missed. Migraine disability was higher among TIRs than TSRs. Conclusion: Migraine attacks had a negative impact on the HRQoL, disability, and work productivity of people with migraine in Japan reporting insufficient efficacy with acute triptan
Pain Ther
treatment, highlighting the need for more effective acute treatment options. Keywords: Adelphi Migraine Disease Specif
Data Loading...
